KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Intangibles (2017 - 2025)

Historic Amortization - Intangibles for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $4.8 million.

  • Biomarin Pharmaceutical's Amortization - Intangibles fell 323.42% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year decrease of 5047.09%. This contributed to the annual value of $43.3 million for FY2024, which is 3046.73% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Amortization - Intangibles of $4.8 million as of Q3 2025, which was down 323.42% from $4.8 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Amortization - Intangibles' 5-year high stood at $17.7 million during Q1 2021, with a 5-year trough of $4.8 million in Q2 2025.
  • For the 5-year period, Biomarin Pharmaceutical's Amortization - Intangibles averaged around $13.5 million, with its median value being $15.7 million (2023).
  • Per our database at Business Quant, Biomarin Pharmaceutical's Amortization - Intangibles surged by 1863.6% in 2021 and then tumbled by 6805.69% in 2024.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Amortization - Intangibles stood at $17.3 million in 2021, then dropped by 5.94% to $16.3 million in 2022, then decreased by 6.29% to $15.2 million in 2023, then crashed by 36.66% to $9.7 million in 2024, then plummeted by 49.78% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $4.8 million for Q2 2025, and $4.8 million during Q1 2025.